Compare NBIX & FUTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | FUTU |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.7B |
| IPO Year | 1996 | 2018 |
| Metric | NBIX | FUTU |
|---|---|---|
| Price | $162.00 | $110.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 4 |
| Target Price | $180.91 | ★ $217.75 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $27.96 |
| Revenue Next Year | $13.14 | $11.89 |
| P/E Ratio | $50.32 | ★ $17.05 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $80.50 |
| 52 Week High | $186.12 | $202.53 |
| Indicator | NBIX | FUTU |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 62.57 |
| Support Level | $153.96 | $91.06 |
| Resistance Level | $169.57 | $155.54 |
| Average True Range (ATR) | 6.37 | 3.66 |
| MACD | -2.08 | 1.39 |
| Stochastic Oscillator | 0.64 | 93.34 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Futu Holdings Ltd is an online broker providing one-stop online investing services.. Through its proprietary digital platforms, Futubull and Moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Group engages in online brokerage services and margin financing services. It generates its revenue in the form of brokerage commission and handling charge services, and interest income. Geographically, it operates in Hong Kong, which derives key revenue and it also has its presence in other countries.